Benjamin F. Edwards & Company Inc. cut its position in shares of Astrazeneca PLC (NYSE:AZN) by 10.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,931 shares of the company’s stock after selling 1,312 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Astrazeneca PLC were worth $373,000 at the end of the most recent quarter.
A number of other hedge funds also recently modified their holdings of AZN. Norges Bank acquired a new position in shares of Astrazeneca PLC during the fourth quarter worth about $8,217,000. Teachers Advisors LLC boosted its stake in shares of Astrazeneca PLC by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 787,179 shares of the company’s stock worth $21,506,000 after buying an additional 30,104 shares during the period. Macquarie Group Ltd. boosted its stake in shares of Astrazeneca PLC by 13.1% in the fourth quarter. Macquarie Group Ltd. now owns 485,066 shares of the company’s stock worth $13,252,000 after buying an additional 56,100 shares during the period. First Financial Bank N.A. Trust Division boosted its stake in shares of Astrazeneca PLC by 0.7% in the first quarter. First Financial Bank N.A. Trust Division now owns 7,517 shares of the company’s stock worth $234,000 after buying an additional 50 shares during the period. Finally, CENTRAL TRUST Co boosted its stake in shares of Astrazeneca PLC by 2.1% in the first quarter. CENTRAL TRUST Co now owns 4,499 shares of the company’s stock worth $140,000 after buying an additional 91 shares during the period. 14.33% of the stock is owned by hedge funds and other institutional investors.
Astrazeneca PLC (NYSE AZN) traded up 0.17% during midday trading on Friday, reaching $29.08. 3,253,688 shares of the company traded hands. The firm has a 50-day moving average price of $32.47 and a 200-day moving average price of $31.40. The firm has a market capitalization of $73.63 billion, a price-to-earnings ratio of 19.08 and a beta of 0.74. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.60. Astrazeneca PLC also saw some unusual options trading on Wednesday. Investors bought 8,259 put options on the company. This is an increase of 1,510% compared to the typical volume of 513 put options.
Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.46. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The company had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same period in the prior year, the company earned $0.83 earnings per share. The firm’s revenue was down 9.9% on a year-over-year basis. Equities analysts predict that Astrazeneca PLC will post $1.85 EPS for the current fiscal year.
The business also recently disclosed a None dividend, which will be paid on Monday, September 11th. Stockholders of record on Friday, August 11th will be paid a $0.44 dividend. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Wednesday, August 9th. Astrazeneca PLC’s payout ratio is 44.92%.
COPYRIGHT VIOLATION NOTICE: “Astrazeneca PLC (AZN) Stake Lowered by Benjamin F. Edwards & Company Inc.” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://stocknewstimes.com/2017/08/12/astrazeneca-plc-azn-position-lowered-by-benjamin-f-edwards-company-inc-updated.html.
Several equities research analysts have weighed in on the stock. Zacks Investment Research cut shares of Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub lowered shares of Astrazeneca PLC from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Cowen and Company reaffirmed a “hold” rating and issued a $34.00 target price on shares of Astrazeneca PLC in a research note on Friday, July 28th. Credit Suisse Group raised shares of Astrazeneca PLC from an “underperform” rating to a “neutral” rating in a research note on Friday, May 12th. Finally, Leerink Swann lowered shares of Astrazeneca PLC from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $36.00 to $31.00 in a research note on Thursday, July 27th. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $33.39.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.